Figures & data
Figure 2 Characterization of PEG-MXene@DDP@R837 and MDR@SHDS. (a) TEM of PEG-MXene; (b) TEM of PEG-MXene@DDP@R837; (c) XPS; (d) Controlled release properties of MDR@SHDS; (e) The morphology of MDR@SHDS at different temperatures of 37°C and 55°C.
![Figure 2 Characterization of PEG-MXene@DDP@R837 and MDR@SHDS. (a) TEM of PEG-MXene; (b) TEM of PEG-MXene@DDP@R837; (c) XPS; (d) Controlled release properties of MDR@SHDS; (e) The morphology of MDR@SHDS at different temperatures of 37°C and 55°C.](/cms/asset/4c702d95-608c-4b0a-bf41-37e49a6ec1e3/dijn_a_12303032_f0002_c.jpg)
Figure 3 In vitro photothermal performance of MDR@SHDS. (a and b) The heating curves of different upon 808 nm laser irradiation (2.0 W/cm2); (c and d) The heating curves of MDR@SHDS at different concentrations; (e) The heating curves upon 5-cycles 808 nm laser exposure (2.0 W/cm 2).
![Figure 3 In vitro photothermal performance of MDR@SHDS. (a and b) The heating curves of different upon 808 nm laser irradiation (2.0 W/cm2); (c and d) The heating curves of MDR@SHDS at different concentrations; (e) The heating curves upon 5-cycles 808 nm laser exposure (2.0 W/cm 2).](/cms/asset/d862e7b7-dd11-474f-b512-0d79c813af49/dijn_a_12303032_f0003_c.jpg)
Figure 4 Controlled-release characteristics of M@SHDS. In vivo near-infrared imaging of 0.1 mL, Cy7 solution (0.015 mg/mL), and M@SHDS loaded with equivalent Cy7 in mice subcutaneously at different time points (1 h, 6 h, 24 h, 48 h, 72 h).
![Figure 4 Controlled-release characteristics of M@SHDS. In vivo near-infrared imaging of 0.1 mL, Cy7 solution (0.015 mg/mL), and M@SHDS loaded with equivalent Cy7 in mice subcutaneously at different time points (1 h, 6 h, 24 h, 48 h, 72 h).](/cms/asset/9ace1705-12b3-4c7c-baa6-d2db43d7d507/dijn_a_12303032_f0004_c.jpg)
Figure 5 In vitro and in vivo biocompatibility assay. (a) Relative cell viabilities of 3T3, Lewis, and RAW264.7 cells exposed to different concentrations of M@SHDS for 24 h; (b and c) The hemolysis assay of various concentrations of M@SHDS and MDR@SHDS.
![Figure 5 In vitro and in vivo biocompatibility assay. (a) Relative cell viabilities of 3T3, Lewis, and RAW264.7 cells exposed to different concentrations of M@SHDS for 24 h; (b and c) The hemolysis assay of various concentrations of M@SHDS and MDR@SHDS.](/cms/asset/98ba1918-5ed2-405c-8af4-c9cc08137e2b/dijn_a_12303032_f0005_c.jpg)
Figure 6 Photographs, HE staining, and Masson staining of M@SHDS in mice subcutaneously at different time points (30 min, Day 7, 14, 21, 28).
![Figure 6 Photographs, HE staining, and Masson staining of M@SHDS in mice subcutaneously at different time points (30 min, Day 7, 14, 21, 28).](/cms/asset/a55bb886-489f-4b45-b312-a9858c3acdbd/dijn_a_12303032_f0006_c.jpg)
Figure 7 In vitro cancer cellular viabilities, proliferation (a) Cellular viabilities of MDR@SHDS with or without PTT (b and c) EdU fluorescence images after treatment with PTT combined with PBS, M@SHDS, and MDR@SHDS.(The label ** indicates p < 0.01, and the label * indicates p < 0.05).
![Figure 7 In vitro cancer cellular viabilities, proliferation (a) Cellular viabilities of MDR@SHDS with or without PTT (b and c) EdU fluorescence images after treatment with PTT combined with PBS, M@SHDS, and MDR@SHDS.(The label ** indicates p < 0.01, and the label * indicates p < 0.05).](/cms/asset/b6853b2e-338f-4939-8460-16d9c08eea93/dijn_a_12303032_f0007_c.jpg)
Figure 8 In vitro cancer cellular apoptosis (a and b) TUNEL fluorescence images after treatment with PTT combined with PBS, M@SHDS, and MDR@SHDS. (The label *** indicates p < 0.001).
![Figure 8 In vitro cancer cellular apoptosis (a and b) TUNEL fluorescence images after treatment with PTT combined with PBS, M@SHDS, and MDR@SHDS. (The label *** indicates p < 0.001).](/cms/asset/96411062-0401-41cd-86ca-46afa9c76b5a/dijn_a_12303032_f0008_c.jpg)
Figure 9 (a and b) Expression levels of surface molecules (CD80 and CD86) on BMDCs after various treatments; (c) Quantification of expression levels of CD80 and CD86 on the surface of BMDCs. (The label *** indicates p < 0.001).
![Figure 9 (a and b) Expression levels of surface molecules (CD80 and CD86) on BMDCs after various treatments; (c) Quantification of expression levels of CD80 and CD86 on the surface of BMDCs. (The label *** indicates p < 0.001).](/cms/asset/f626d4c3-305b-457a-8641-bf7e7262d187/dijn_a_12303032_f0009_c.jpg)
Figure 10 Thermal images of mice bearing tumor after injection of PBS or MDR@SHDS, followed by being exposed to 808 nm irradiation.
![Figure 10 Thermal images of mice bearing tumor after injection of PBS or MDR@SHDS, followed by being exposed to 808 nm irradiation.](/cms/asset/5f119db3-2b7b-44ef-8bdd-e062a3916c70/dijn_a_12303032_f0010_c.jpg)
Figure 11 (a) Images of tumors at 13 days post-treatment; (b) HE stains of tumors at 13 days post-treatment.
![Figure 11 (a) Images of tumors at 13 days post-treatment; (b) HE stains of tumors at 13 days post-treatment.](/cms/asset/9e6d8051-23f6-4b01-80ed-a8548573ed5f/dijn_a_12303032_f0011_c.jpg)
Figure 12 (a) Tumor growth curves. (b) Body weight changes of C57 mice bearing Lewis tumors were recorded every other day after different treatments.
![Figure 12 (a) Tumor growth curves. (b) Body weight changes of C57 mice bearing Lewis tumors were recorded every other day after different treatments.](/cms/asset/d1a86a1b-9154-4f9c-b967-1fb66fbccee8/dijn_a_12303032_f0012_c.jpg)
Data Sharing Statement
Any display item and related data are available upon request.